Ocrelizumab Discontinuation After Recurrent Serious Infections in Clinically Stable Primary Progressive Multiple Sclerosis: A Case Report. (PubMed, Cureus) - Sep 23, 2026 - "This case underscores the need to reassess long-term therapy according to recent disease activity, cumulative treatment exposure, immunologic monitoring, infection history, functional status, comorbidities, care context, and patient goals. A single case cannot establish age-based or universal discontinuation thresholds; instead, it supports individualized shared decision-making regarding treatment continuation, interval extension, temporary interruption, or discontinuation."
Journal • CNS Disorders • Gastrointestinal Disorder • Infectious Disease • Inflammation • Multiple Sclerosis • Pneumonia • Respiratory Diseases
|
|
Lamisa Hassan; Rithvik Seri; Shane Wilson; Stephanie Hang; Tyler Lo
|